Full-Time

Senior Scientist I/II

Epigenetic Editing Technologies

Posted on 6/27/2024

Mammoth Biosciences

Mammoth Biosciences

51-200 employees

Develops CRISPR-based diagnostic tests

Biotechnology
Healthcare

Compensation Overview

$150k - $182.3kAnnually

Mid, Senior

Daly City, CA, USA

Position is onsite in Brisbane, CA.

Category
Bioinformatics
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Molecular Biology, Cell Biology, Bioengineering or a related discipline; 3+ years of relevant professional experience in industry or academia, following completion of PhD. For non-PhD candidates with a Bachelor's degree, 8+ years of professional experience is required
  • 2+ years of hands-on experience designing and refining fusion proteins for CRISPR or other DNA binding proteins (ZNF, TALE)
  • 2+ years of hands-on experience designing, executing, and analyzing CRISPRa/i or epigenetic editing experiments in mammalian cells
  • 3+ years hands-on experience in at least two of the following areas:
  • Epigenetic characterization assays including bisulfite sequencing (targeted or whole genome), EM-seq, ChIP-qPCR, and/or ChIP-seq
  • Flow cytometry and/or fluorescence-activated cell sorting (FACS)
  • Transcript/protein quantification assays including RT-qPCR; d/ddPCR, RNA-seq, ELISA, and/or MSD
  • Automated methods for high-throughput molecular/cell biology workflows
Responsibilities
  • Contribute creatively to the design of new epigenetic editing tools through ideation and literature review
  • Develop scalable assays for measuring gene and protein expression, epigenetic state, and/or cellular phenotype
  • Plan, design and execute experiments for CRISPR tool evaluation
  • Provide instruction to junior team members
  • Document experiments in electronic laboratory notebooks and present results at internal meetings
  • Disclose inventions to the IP team for patenting
  • Other duties as assigned

Mammoth Biosciences focuses on molecular diagnostics by using CRISPR technology to develop rapid diagnostic tests that can identify ailments, including infectious diseases like COVID-19, at the point of care. This allows for immediate results, reducing the wait time associated with traditional lab tests. The company differentiates itself with its versatile CRISPR-based detection platform, which offers a wide range of testing applications. Mammoth's goal is to enhance the accessibility and efficiency of diagnostic testing in response to global health challenges.

Company Stage

Late Stage VC

Total Funding

$353.3M

Headquarters

Brisbane, California

Founded

2017

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-4%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Regeneron enhances CRISPR-based gene-editing capabilities.
  • $95 million investment from Regeneron boosts financial resources for CRISPR advancements.
  • Presentation at ASGCT highlights progress in ultracompact CRISPR systems for genetic diseases.

What critics are saying

  • Emerging competition from companies like VedaBio challenges market position.
  • Recent layoffs may indicate internal challenges or strategic shifts.
  • Regulatory hurdles could delay market entry for gene-editing therapies.

What makes Mammoth Biosciences unique

  • Mammoth Biosciences leverages novel CRISPR systems like Cas12, Cas13, and Cas14.
  • Co-founded by CRISPR pioneer Jennifer Doudna, enhancing credibility and innovation.
  • Focuses on democratizing disease detection with affordable, real-time point-of-care tests.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Medical, dental, & vision

401(k)

Unlimited vacation

Transportation subsidy

Onsite amenities

Happy hours

INACTIVE